Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy

Journal of the National Cancer Institute

Volumn 88, Issue 2, 1996, Pages 100-108

  Restifo, Nicholas P ^a,b   Marincola, Francesco M ^a   Kawakami, Yutaka ^a   Taubenberger, Jeff ^a   Yannelli, John R ^a   Rosenberg, Steven A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA 2 MICROGLOBULIN; CD8 ANTIGEN; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADULT; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MELANOMA; PROTEIN SYNTHESIS REGULATION; SKIN BIOPSY; T LYMPHOCYTE ACTIVATION;

ADULT; BASE SEQUENCE; BETA 2-MICROGLOBULIN; BLOTTING, NORTHERN; BLOTTING, WESTERN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MHC CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MALE; MELANOMA; MIDDLE AGED; MOLECULAR SEQUENCE DATA; RNA, MESSENGER; RNA, NEOPLASM; SKIN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0029670776     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.2.100     Document Type: Article

References (57)

1. Topalian SL. Cell transfer therapy: preclinical studies. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer. 2nd ed. Philadelphia: Lippincott, 1995:467-86.
2. Peoples GE. Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Everlein TJ. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 1995; 92:432-6.
3. Hoppe RT, Medeiros LJ, Warnke RA, Wood GS. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 1995;32:448-53.
4. Rosenberg SA, Yannelli JR, Yang JC, Topalian SL, Schwartzentruber DF, Weber JS, et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 [see comment citation in Medline]. J Natl Cancer Inst 1994;86:1159-66.
5. Ikarashi H, Fujita K, Takakuwa K, Kodama S, Tokunaga A, Takahashi T, et al. Immunomodulation in patients with epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Cancer Res 1994; 54:190-6.
6. Peoples GE, Blotnick S, Takahashi K, Freeman MR, Klagsbrun M, Eberlein TJ. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role. Proc Natl Acad Sci U S A 1995;92:6547-51.
7. Schoof DD, Terashima Y, Peoples GE, Goedegebuure PS, Andrews JV. CD4+ T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells. Cell Immunol 1993; 150: 114-23.
8. Yoshino I, Peoples GE, Goedegebuure PS, Maziarz R, Eberlein TJ. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J Immunol 1994; 152:2393-400.
9. Qin H, Chen W, Takahashi M, Disis ML, Byrd DR, McCahill L, et al. CD4+ T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res 1995;55:2984-7.
10. Fisk B, Blevins TL, Wharton JT, Ioannides CG. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995; 181: 2109-17.
11. Rosenberg SA. Cell transfer therapy: clinical applications. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Biologic therapy of cancer. 2nd ed. Philadelphia: Lippincott, 1995:487-506.
12. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice [see comment citation in Medline]. Science 1992; 258:1795-8.
13. Restifo NP, Kawakami Y, Marincola F, Shamamian P, Taggarse A, Esquivel F, et al. Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. J Immunother 1993; 14:182-90.
14. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mulé JJ, Rosenberg SA, et al. Identification of human cancers deficient in antigen processing. J Exp Med 1993;177:265-72.
15. Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL, et al. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994; 179:335-40.
16. Fenton RG, Longo DL. Genetic instability and tumor cell variation: implications for immunotherapy [editorial; see comment citation in Medline]. J Natl Cancer Inst 1995;87:241-3.
17. Hansen TH, Carreno BM, Sachs DH. The major histocompatibility complex. In: Paul W, editor. Fundamental immunology. 3rd ed. New York: Raven Press, 1993:577-628.
18. Neumann H. Cavalie A, Jenne DE, Wekerle H. Induction of MHC class I genes in neurons. Science 1995;269:549-52.
19. Rammensee HG, Falk K, Rotzschke O. MHC molecules as peptide receptors. Curr Opin Immunol 1993:5:35-44.
20. Brown JH, Jardetzky TS, Gorga JC, Stern JL, Urban RG, Strominger JL, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1 [see comment citation in Medline]. Nature 1993;364:33-9.
21. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature 1987;329:506-12.
22. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens. Nature 1987;329:512-8.
23. Wilson IA, Fremont DH. Structural analysis of MHC class I molecules with bound peptide antigens. Semin Immunol 1993;5:75-80.
24. Stura EA. Matsumura M, Fremont DH, Saito Y, Peterson PA, Wilson IA. Crystallization of murine major histocompatibility complex class I H-2Kb with single peptides. J Mol Biol 1992;228:975-82.
25. Matsumura M, Fremont DH, Peterson PA, Wilson IA. Emerging principles for the recognition of peptide antigens by MHC class I molecules [see comment citation in Medline]. Science 1992;257:927-34.
26. b [see comment citation in Medline]. Science 1992;257:919-27.
27. Zugel U, Schoel B, Kaufmann SH. Beta 2-microglobulin independent presentation of exogenously added foreign peptide and endogenous self-epitope by MHC class I alpha-chain to a cross-reactive CD8+ CTL clone. J Immunol 1994;153:4070-80.
28. Sumida T, Furukawa M, Sakamoto A, Namekawa T, Maeda T, Zijlstra M, et al. Prevention of insulitis and diabetes in beta 2-microglobulin-deficient non-obese diabetic mice. Int Immunol 1994;6:1445-9.
29. + cytolytic T cells [see comment citation in Medline). Nature 1990;344:742-6.
30. Sugita M, Brenner MB. An unstable beta 2-microglobulin: major histocompatibility complex class I heavy chain intermediate dissociates from calnexin and then is stabilized by binding peptide. J Exp Med 1994; 180:2163-71.
31. Bicknell DC, Rowan A, Bodmer WF. Beta 2-microglobulin gene mutations: a study of established colorectal cell lines and fresh tumors. Proc Natl Acad Sci U S A 1994;91:4751-6.
32. Bodmer WF, Browning MJ, Krausa P, Rowan A, Bicknell DC. Bodmer JG. Tumor escape from immune response by variation in HLA expression and other mechanisms. Ann N Y Acad Sci 1993;690:42-9.
33. Momburg F, Koch S. Selective loss of beta 2-microglobulin mRNA in human colon carcinoma. J Exp Med 1989;169:309-14.
34. Wang Z, Cao Y, Albino AP, Zeff RA. Houghton A, Ferrone S. Lack of HLA class 1 antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. J Clin Invest 1993;91:684-92.
35. D'Urso CM, Wang ZG, Cao Y, Tatake R. Zeff RA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in β2m gene expression. J Clin Invest 1991;87:284-92.
36. Marincola FM, Shamamian P, Alexander RB, Gnarra JR, Turetskaya RL. Nedospasov SA. et al. Loss of HLA haplotype and B locus down-regulation in melanoma cells lines. J Immunol 1994;153:1225-37.
37. Rosenberg SA. The gene therapy of cancer. Prev Med 1994;23:624-6.
38. Topalian SL, Solomon D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989;142:3714-25.
39. Restifo NP, Esquivel F, Asher AL, Stotter H, Barth RJ, Bennink JR. et al. Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response. J Immunol 1991;147:1453-9.
40. Cole DJ, Taubenberger JK, Pockaj BA, Yannelli JR, Carter C, Carrasquillo J. et al. Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes. Cancer Immunol Immunother 1994;38:299-303.
41. Topalian SL, Rivoltini L, Mancini M, Ng J, Hartzman RJ, Rosenberg SA. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int J Cancer 1994;58:69-79.
42. O'Neil BH, Kawakami Y, Restifo NP, Bennink JR, Yewdell JW, Rosenberg SA. Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA. J Immunol 1993;151:1410-8.
43. Hammond SA, Bollinger RC, Tobery TW, Silliciano RF. Transporter-independent processing of HIV-1 envelope protein for recognition by CD8+ T cells. Nature 1993;364:158-61.
44. Henderson RA, Michel H. Sakaguchi K, Shabanowitz J, Appella E, Hunt DF. et al. HLA-A2.1-associated peptides from a mutant cell line: a second pathway of antigen presentation [see comment citations in Medline). Science 1992;255:1264-6.
45. Townsend A, Bastin J, Gould K, Brownlee G, Andrew M, Coupar B, et al. Detective presentation to class l-restricted cylotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J Exp Med 1988;168:1211-24.
46. Kawakami Y, Eliyahu S, Sakaguctii K, Robbins PF, Rivoltini L, Yannelli JR, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180:347-52.
47. Kageshita T, Wang Z, Calorini L, Yoshii A, Kimura T, Ono T, et al. Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens. Cancer Res 1993, 53:3349-54.
48. Branch P, Bicknell DC, Rowan A. Bodmer WF, Karran P. Immune surveillance in colorectal carcinoma [letter]. Nat Genet 1995;9:231-2.
49. Restifo NP, Spiess PJ, Karp SE, Mulé JJ, Rosenberg SA. A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med 1992;175:1423-31.
50. Esquivel F, Yewdell J, Bennink J, RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes. J Exp Med 1992;175:163-8.
51. Maio M, Altomonte M, Tatake R, Zeff RA. Ferrone S. Reduction in susceptibility to natural killer cell-mediated lysis of human FO-I melanoma cells after induction of HLA class 1 antigen expression by transfection with β2m gene. J Clin Invest 1991;88:282-9.
52. Karre K, Express yourself or die: peptides, MHC molecules, and NK cells [see comment citation in Medline]. Science 1995;267:978-9.
53. Malnati MS, Peruzzi M, Parker KC, Biddison WE, Ciceone E, Moretta A, et al. Peptide specificity in the recognition of MHC class I by natural killer cell clones [see comment citation in Medline). Science 1995;267:1016-8.
54. Zijlstra M, Li E, Sajjadi F, Subramani S, Jaenisch R, Germ-line transmission of a distrupted β2-microglobulin gene produced by homologous recombination in embryonic stem cells. Nature 1989;342:435-8.
55. Zijlstra M, Auchincloss H Jr. Loring JM, Chase CM, Russell PS, Jaenisch R. Skin graft rejection by beta 2-microglobulin-deficienl mice. J Exp Med 1992;175:885-93.
56. Eichelberger M, Allan W, Zijlstra M, Jaenisch R, Doherty PC. Clearance of influenza virus respiratory infection in mice lacking class I major histocompatibility complex-restricted CD8+ T cells. J Exp Med 1991; 174:875-80.
57. Hou S, Doherty PC, Zijlstra M, Jaenisch R, Katz JM. Delayed clearance of Sendai virus in mice lacking class 1 MHC-restricted CD8+ T cells. J Immunol 1992;149:1319-25.